Castle Biosciences (NASDAQ:CSTL) Given New $39.00 Price Target at Robert W. Baird

Castle Biosciences (NASDAQ:CSTL) had its price objective upped by Robert W. Baird from $37.00 to $39.00 in a research report released on Tuesday, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other equities analysts have also recently issued reports on the stock. Stephens restated an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. KeyCorp increased their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research report on Tuesday. Canaccord Genuity Group lifted their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Finally, BTIG Research increased their price target on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, October 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Castle Biosciences currently has a consensus rating of “Buy” and a consensus price target of $37.00.

Castle Biosciences Trading Down 7.4 %

Shares of NASDAQ CSTL opened at $31.15 on Tuesday. The company has a market cap of $860.05 million, a PE ratio of -222.50 and a beta of 0.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12. The firm’s 50 day moving average price is $30.70 and its 200-day moving average price is $25.67. Castle Biosciences has a 52-week low of $16.20 and a 52-week high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a negative return on equity of 0.77% and a negative net margin of 1.08%. The business had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. During the same period last year, the business posted ($0.26) EPS. On average, equities research analysts expect that Castle Biosciences will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Castle Biosciences news, Director Daniel Bradbury sold 7,883 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $26.65, for a total transaction of $210,081.95. Following the completion of the sale, the director now owns 8,550 shares of the company’s stock, valued at approximately $227,857.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Daniel Bradbury sold 7,883 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $26.65, for a total value of $210,081.95. Following the completion of the sale, the director now directly owns 8,550 shares of the company’s stock, valued at $227,857.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Derek J. Maetzold sold 1,972 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $32.27, for a total transaction of $63,636.44. Following the sale, the insider now owns 91,664 shares in the company, valued at $2,957,997.28. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 19,694 shares of company stock valued at $563,497. 7.20% of the stock is owned by company insiders.

Institutional Trading of Castle Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE grew its holdings in Castle Biosciences by 1,889.2% during the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after buying an additional 4,383 shares in the last quarter. Assetmark Inc. boosted its position in shares of Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after acquiring an additional 748 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Castle Biosciences by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock valued at $152,000 after acquiring an additional 2,093 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Castle Biosciences by 10.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock valued at $215,000 after acquiring an additional 952 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Castle Biosciences in the 2nd quarter worth $218,000. Institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.